Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
Enanta Pharmaceuticals (NASDAQ:ENTA) announced its upcoming presentations at the 13th International RSV Symposium (RSV 2025) in Iguazu Falls, Brazil, from March 12-15. The company will showcase four presentations highlighting its respiratory syncytial virus (RSV) program:
The main oral presentation will feature results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, scheduled for March 14. A late-breaker poster will present data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for RSV treatment in young children.
Two additional poster presentations will focus on: (1) distinctions among fusion, N, and L inhibitors regarding preclinical antiviral effect and resistance profiles, and (2) PK and PK/PD results from the EDP-323 Phase 2 human challenge study. All presentations will be delivered at the Bourbon Cataratas do Iguazu venue.
Enanta Pharmaceuticals (NASDAQ:ENTA) ha annunciato le sue prossime presentazioni al 13° Simposio Internazionale RSV (RSV 2025) a Iguazu Falls, Brasile, dal 12 al 15 marzo. L'azienda presenterà quattro interventi che evidenziano il suo programma sul virus respiratorio sinciziale (RSV):
La principale presentazione orale presenterà i risultati di uno studio di sfida umana di Fase 2 su EDP-323, un inibitore della proteina L dell’RSV, previsto per il 14 marzo. Un poster di ultima ora presenterà dati da uno studio di Fase 2 su zelicapavir, un inibitore della proteina N, per il trattamento dell’RSV nei bambini piccoli.
Due ulteriori presentazioni poster si concentreranno su: (1) le distinzioni tra inibitori di fusione, N e L riguardo all'effetto antivirale preclinico e ai profili di resistenza, e (2) i risultati di PK e PK/PD dallo studio di sfida umana di Fase 2 su EDP-323. Tutte le presentazioni si terranno presso il venue Bourbon Cataratas do Iguazu.
Enanta Pharmaceuticals (NASDAQ:ENTA) anunció sus próximas presentaciones en el 13º Simposio Internacional sobre RSV (RSV 2025) en las Cataratas del Iguazú, Brasil, del 12 al 15 de marzo. La compañía mostrará cuatro presentaciones que destacan su programa sobre el virus sincitial respiratorio (RSV):
La presentación oral principal presentará los resultados de un estudio de desafío humano de Fase 2 de EDP-323, un inhibidor de la proteína L del RSV, programado para el 14 de marzo. Un póster de última hora presentará datos de un estudio de Fase 2 de zelicapavir, un inhibidor de la proteína N, para el tratamiento del RSV en niños pequeños.
Dos presentaciones adicionales en póster se centrarán en: (1) las distinciones entre los inhibidores de fusión, N y L en relación con el efecto antiviral preclínico y los perfiles de resistencia, y (2) los resultados de PK y PK/PD del estudio de desafío humano de Fase 2 de EDP-323. Todas las presentaciones se llevarán a cabo en el lugar Bourbon Cataratas do Iguazu.
Enanta Pharmaceuticals (NASDAQ:ENTA)는 3월 12일부터 15일까지 브라질 이구아수 폭포에서 열리는 제13회 국제 RSV 심포지엄 (RSV 2025)에서 다가오는 발표를 발표했습니다. 이 회사는 호흡기 세포융합 바이러스(RSV) 프로그램을 강조하는 네 가지 발표를 선보일 예정입니다:
주요 구두 발표는 EDP-323에 대한 2상 인간 도전 연구의 결과를 포함하며, 3월 14일로 예정되어 있습니다. 늦은 시간에 발표될 포스터에서는 어린이의 RSV 치료를 위한 zelicapavir의 2상 연구 데이터를 제시합니다.
추가로 두 개의 포스터 발표는 (1) 융합, N 및 L 억제제 간의 전임상 항바이러스 효과 및 저항성 프로파일에 대한 구별, (2) EDP-323의 2상 인간 도전 연구에서의 PK 및 PK/PD 결과에 초점을 맞출 것입니다. 모든 발표는 Bourbon Cataratas do Iguazu 장소에서 진행됩니다.
Enanta Pharmaceuticals (NASDAQ:ENTA) a annoncé ses prochaines présentations lors du 13ème Symposium International sur le RSV (RSV 2025) aux chutes d'Iguazu, au Brésil, du 12 au 15 mars. L'entreprise présentera quatre interventions mettant en avant son programme sur le virus respiratoire syncytial (RSV) :
La présentation orale principale mettra en avant les résultats d'une étude de défi humain de Phase 2 sur EDP-323, un inhibiteur de la protéine L du RSV, prévue pour le 14 mars. Un poster de dernière minute présentera des données d'une étude de Phase 2 sur le zelicapavir, un inhibiteur de la protéine N, pour le traitement du RSV chez les jeunes enfants.
Deux présentations supplémentaires sous forme de poster se concentreront sur : (1) les distinctions entre les inhibiteurs de fusion, N et L en ce qui concerne l'effet antiviral préclinique et les profils de résistance, et (2) les résultats de PK et PK/PD de l'étude de défi humain de Phase 2 sur EDP-323. Toutes les présentations auront lieu au lieu Bourbon Cataratas do Iguazu.
Enanta Pharmaceuticals (NASDAQ:ENTA) hat seine bevorstehenden Präsentationen beim 13. Internationalen RSV-Symposium (RSV 2025) in den Iguazu-Fällen, Brasilien, vom 12. bis 15. März angekündigt. Das Unternehmen wird vier Präsentationen vorstellen, die sein Programm zum respiratorischen Synzytialvirus (RSV) hervorheben:
Die Hauptpräsentation wird die Ergebnisse einer Phase-2-Menschlichen-Herausforderungsstudie zu EDP-323, einem RSV L-Protein-Inhibitor, präsentieren, die für den 14. März geplant ist. Ein Spätbrecher-Poster wird Daten aus einer Phase-2-Studie zu Zelicapavir, einem N-Protein-Inhibitor, zur RSV-Behandlung bei kleinen Kindern vorstellen.
Zwei zusätzliche Posterpräsentationen werden sich auf Folgendes konzentrieren: (1) Unterschiede zwischen Fusions-, N- und L-Inhibitoren hinsichtlich der präklinischen antiviralen Wirkung und der Resistenzprofile und (2) PK- und PK/PD-Ergebnisse aus der EDP-323 Phase-2-Menschlichen-Herausforderungsstudie. Alle Präsentationen finden im Bourbon Cataratas do Iguazu statt.
- None.
- None.
Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation. Data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for the treatment of RSV in young children will be presented in a late breaker poster. An additional poster will highlight distinctions among fusion, N, and L inhibitors with respect to preclinical antiviral effect and resistance profiles, while a third poster will detail PK and PK/PD results from the EDP-323 Phase 2 human challenge study.
Oral Presentation:
Date: Friday, March 14, 2025
Time: 12:00 – 12:15 PM Brasília Time (BRT)/11:00 – 11:15 AM Eastern Daylight Time (EDT)
Session Name: RSV Monoclonal Antibodies and Antivirals
Abstract ID: ARBI0162
Title: “EDP-323, a First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV: Results from a Phase 2a Human Viral Challenge Study”
Location: Bourbon Cataratas do Iguazu, Bourbon Ballroom
Presenter Name: John P. DeVincenzo, M.D.
Late Breaker Poster Presentation:
Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Session Name: RSV Monoclonal Antibodies and Antivirals
Abstract ID: ARBI0332
Poster Number: 253
Title: “A Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young Children”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: John P. DeVincenzo, M.D.
Poster Presentations:
Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Abstract ID: ARBI0249
Poster Number: 161
Title: “In Vitro Characterization of Respiratory Syncytial Virus Inhibitors”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: Michael Rhodin, Ph.D.
Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Abstract ID: ARBI0158
Poster Number: 153
Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: Kimberly Elmore (Mills), PharmD
Further information about RSV 2025 can be found here.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312968329/en/
Jennifer Viera
617-744-3848
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
FAQ
What are the key RSV treatments being presented by Enanta Pharmaceuticals (ENTA) at RSV 2025?
When and where will Enanta Pharmaceuticals (ENTA) present its RSV program data in March 2025?
What are the presentation times for ENTA's Phase 2 EDP-323 results at RSV 2025?
How many presentations will Enanta Pharmaceuticals (ENTA) deliver at the RSV 2025 symposium?
